BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang J, Zhao Y, Hou T, Zeng H, Kalambhe D, Wang B, Shen X, Huang Y. Macrophage-based nanotherapeutic strategies in ulcerative colitis. Journal of Controlled Release 2020;320:363-80. [DOI: 10.1016/j.jconrel.2020.01.047] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang X, Gu H, Zhang H, Xian J, Li J, Fu C, Zhang C, Zhang J. Oral Core-Shell Nanoparticles Embedded in Hydrogel Microspheres for the Efficient Site-Specific Delivery of Magnolol and Enhanced Antiulcerative Colitis Therapy. ACS Appl Mater Interfaces 2021;13:33948-61. [PMID: 34261306 DOI: 10.1021/acsami.1c09804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Lu J, Liu D, Tan Y, Deng F, Li R. M1 Macrophage exosomes MiR-21a-5p aggravates inflammatory bowel disease through decreasing E-cadherin and subsequent ILC2 activation. J Cell Mol Med 2021;25:3041-50. [PMID: 33569850 DOI: 10.1111/jcmm.16348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang G, Ma L, Bai L, Li M, Guo T, Tian B, He Z, Fu Q. Inflammatory microenvironment-targeted nanotherapies. J Control Release 2021;334:114-26. [PMID: 33887284 DOI: 10.1016/j.jconrel.2021.04.018] [Reference Citation Analysis]
4 Ibaraki H, Takeda A, Arima N, Hatakeyama N, Takashima Y, Seta Y, Kanazawa T. In Vivo Fluorescence Imaging of Passive Inflammation Site Accumulation of Liposomes via Intravenous Administration Focused on Their Surface Charge and PEG Modification. Pharmaceutics 2021;13:104. [PMID: 33466905 DOI: 10.3390/pharmaceutics13010104] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wu MM, Wang QM, Huang BY, Mai CT, Wang CL, Wang TT, Zhang XJ. Dioscin ameliorates murine ulcerative colitis by regulating macrophage polarization. Pharmacol Res 2021;172:105796. [PMID: 34343656 DOI: 10.1016/j.phrs.2021.105796] [Reference Citation Analysis]
6 Han H, Ke L, Wang H, Gao G, zhang Y, Rao P, Zhou J, Tirosh O, Schwartz B. Incidental Nanoparticles in Black Tea Infusion: Carriers of Bioactives Fortifying Protection on Intestinal Mucosal Cells Against Oxidative Stresses. Food Biophysics. [DOI: 10.1007/s11483-021-09708-5] [Reference Citation Analysis]
7 Liang Y, He Q, Duan L, Gong H, Zu M, Xie D, Xiao B. Fluorinated hyaluronates endow oral nanoparticles with mucus penetration and colonic macrophage targeting properties. Smart Materials in Medicine 2021;2:250-9. [DOI: 10.1016/j.smaim.2021.07.003] [Reference Citation Analysis]
8 Zu M, Ma Y, Cannup B, Xie D, Jung Y, Zhang J, Yang C, Gao F, Merlin D, Xiao B. Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases. Adv Drug Deliv Rev 2021;176:113887. [PMID: 34314785 DOI: 10.1016/j.addr.2021.113887] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 19.0] [Reference Citation Analysis]
9 Fang G, Tang B. Current advances in the nano-delivery of celastrol for treating inflammation-associated diseases. J Mater Chem B 2020;8:10954-65. [PMID: 33174584 DOI: 10.1039/d0tb01939a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Qiu H, Gong H, Bao Y, Jiang H, Tong W. Reactive oxygen species-scavenging hollow MnO2 nanozymes as carriers to deliver budesonide for synergistic inflammatory bowel disease therapy. Biomater Sci 2021. [PMID: 34882157 DOI: 10.1039/d1bm01525g] [Reference Citation Analysis]
11 Li Y, Yang S, Lun J, Gao J, Gao X, Gong Z, Wan Y, He X, Cao H. Inhibitory Effects of the Lactobacillus rhamnosus GG Effector Protein HM0539 on Inflammatory Response Through the TLR4/MyD88/NF-кB Axis. Front Immunol 2020;11:551449. [PMID: 33123130 DOI: 10.3389/fimmu.2020.551449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Shi J, Zhang Y, Zhang X, Chen R, Wei J, Hou J, Wang B, Lai H, Huang Y. Remodeling immune microenvironment in periodontitis using resveratrol liposomes as an antibiotic-free therapeutic strategy. J Nanobiotechnology 2021;19:429. [PMID: 34930286 DOI: 10.1186/s12951-021-01175-x] [Reference Citation Analysis]
13 Xu C, Chen S, Chen C, Ming Y, Du J, Mu J, Luo F, Huang D, Wang N, Lin Z, Weng Z. Colon-targeted oral nanoparticles based on ROS-scavenging hydroxyethyl starch-curcumin conjugates for efficient inflammatory bowel disease therapy. Int J Pharm 2022;623:121884. [PMID: 35661797 DOI: 10.1016/j.ijpharm.2022.121884] [Reference Citation Analysis]
14 Xu S, Yang Q, Wang R, Tian C, Ji Y, Tan H, Zhao P, Kaplan DL, Wang F, Xia Q. Genetically engineered pH-responsive silk sericin nanospheres with efficient therapeutic effect on ulcerative colitis. Acta Biomater 2022;144:81-95. [PMID: 35288310 DOI: 10.1016/j.actbio.2022.03.012] [Reference Citation Analysis]
15 Yang M, Zhang Y, Ma Y, Yan X, Gong L, Zhang M, Zhang B. Nanoparticle-based therapeutics of inflammatory bowel diseases: a narrative review of the current state and prospects. Journal of Bio-X Research 2020;3:157-73. [DOI: 10.1097/jbr.0000000000000078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Ibaraki H, Hatakeyama N, Arima N, Takeda A, Seta Y, Kanazawa T. Systemic delivery of siRNA to the colon using peptide modified PEG-PCL polymer micelles for the treatment of ulcerative colitis. Eur J Pharm Biopharm 2021:S0939-6411(21)00358-1. [PMID: 34963657 DOI: 10.1016/j.ejpb.2021.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zhao Y, Yang Y, Zhang J, Wang R, Cheng B, Kalambhe D, Wang Y, Gu Z, Chen D, Wang B, Huang Y. Lactoferrin-mediated macrophage targeting delivery and patchouli alcohol-based therapeutic strategy for inflammatory bowel diseases. Acta Pharm Sin B 2020;10:1966-76. [PMID: 33163347 DOI: 10.1016/j.apsb.2020.07.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
18 Zhang L, Yu L, Wei Y. Oral Administration of Cryptotanshinone-Encapsulated Nanoparticles for the Amelioration of Ulcerative Colitis. Cel Mol Bioeng . [DOI: 10.1007/s12195-021-00711-x] [Reference Citation Analysis]
19 Wang YX, Lin C, Cui LJ, Deng TZ, Li QM, Chen FY, Miao XP. Mechanism of M2 macrophage-derived extracellular vesicles carrying lncRNA MEG3 in inflammatory responses in ulcerative colitis. Bioengineered 2021;12:12722-39. [PMID: 34895044 DOI: 10.1080/21655979.2021.2010368] [Reference Citation Analysis]
20 Hu F, Lou N, Jiao J, Guo F, Xiang H, Shang D. Macrophages in pancreatitis: Mechanisms and therapeutic potential. Biomed Pharmacother. 2020;131:110693. [PMID: 32882586 DOI: 10.1016/j.biopha.2020.110693] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
21 Sun T, Kwong CHT, Gao C, Wei J, Yue L, Zhang J, Ye RD, Wang R. Amelioration of ulcerative colitis via inflammatory regulation by macrophage-biomimetic nanomedicine. Theranostics 2020;10:10106-19. [PMID: 32929337 DOI: 10.7150/thno.48448] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
22 Du Y, Rong L, Cong Y, Shen L, Zhang N, Wang B. Macrophage polarization: an effective approach to targeted therapy of inflammatory bowel disease. Expert Opin Ther Targets 2021;25:191-209. [PMID: 33682588 DOI: 10.1080/14728222.2021.1901079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Liu C, Huang S, Wu Z, Li T, Li N, Zhang B, Han D, Wang S, Zhao J, Wang J. Cohousing-mediated microbiota transfer from milk bioactive components-dosed mice ameliorate colitis by remodeling colonic mucus barrier and lamina propria macrophages. Gut Microbes 2021;13:1-23. [PMID: 33789528 DOI: 10.1080/19490976.2021.1903826] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Li R, Ma Y, Hong J, Ding Y. Nanoengineered therapy aiming at the etiology of rheumatoid arthritis. Nano Today 2022;42:101367. [DOI: 10.1016/j.nantod.2021.101367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Wu Z, Zeng H, Zhang L, Pu Y, Li S, Yuan Y, Zhang T, Wang B. Patchouli Alcohol: a Natural Sesquiterpene Against Both Inflammation and Intestinal Barrier Damage of Ulcerative Colitis. Inflammation 2020;43:1423-35. [PMID: 32388657 DOI: 10.1007/s10753-020-01219-8] [Reference Citation Analysis]
26 Huang Z, Shi Y, Wang H, Chun C, Chen L, Wang K, Lu Z, Zhao Y, Li X. Protective Effects of Chitosan-Bilirubin Nanoparticles Against Ethanol-Induced Gastric Ulcers. Int J Nanomedicine 2021;16:8235-50. [PMID: 34992363 DOI: 10.2147/IJN.S344805] [Reference Citation Analysis]
27 Ibaraki H, Hatakeyama N, Takeda A, Arima N, Kanazawa T. Multifunctional peptide carrier-modified polymer micelle accelerates oral siRNA-delivery to the colon and improves gene silencing-mediated therapeutic effects in ulcerative colitis. Journal of Drug Delivery Science and Technology 2022. [DOI: 10.1016/j.jddst.2022.103481] [Reference Citation Analysis]
28 Cui H, Shen Y, Schiffelers RM, Hennink WE. Transform nanomedicine with breakthrough thinking? J Control Release 2021;330:1130-1. [PMID: 33189787 DOI: 10.1016/j.jconrel.2020.11.018] [Reference Citation Analysis]